

A new approach to developing a vaccine against vivax malaria

September 21 2018



Human reticulocyte-derived exosomes could be used as a novel vaccine platform against vivax malaria. Credit: del Portillo et al.

A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, both at IGTP and ISGlobal, indicates the possibility of using small vesicles (or exosomes) secreted by



immature red blood cells as a vaccine platform against malaria. The paper was published in the journal *Scientific Reports*.

Reticulocytes are immature red blood cells that selectively eliminate cellular proteins through the release of tiny vesicles called exosomes. Previous work by the Del Portillo group in a mouse <u>malaria</u> model had shown that exosomes derived from reticulocytes contain proteins from the parasite and could work as a vaccine when used to immunize other mice. By using proteomic analysis, the new study identifies 360 new proteins present in human reticulocyte exosomes. "This comprehensive list of proteins from these human exosomes represents a valuable resource for better understanding how the malaria parasite infects <u>red</u> <u>blood cells</u>," says Fernandez-Becerra. For instance, some of the new proteins identified are involved in the entrance of Plasmodium vivax into reticulocytes, thus partially explaining failure of in vitro culture systems.

The study also discovered the presence of proteins called HLA-class I in exosomes derived from human cord blood reticulocytes (HuRex). Such molecules are in charge of unmasking <u>protein</u> fragments from the parasite so the immune system can destroy infected cells. To determine if reticulocyte exosomes can trigger immunity against Plasmodium vivax, a functional assay demonstrated that HuRex are actively uptaken by dendritic cells, which are key sentinel cells that regulate the initiation of immune responses. "These findings converge with other recent findings in the field, and should spark new preventive cellular vaccines against malaria," explain Javier Martínez-Picado, ICREA Research Professor, and Núria Izquierdo-Useros at IRSI-Caixa.

"Altogether, these results support further studies of reticulocyte exosomes from infections for vaccine antigen discovery and of HuRex as a potential new <u>vaccine</u> delivery platform for eliciting cytotoxic T-cell responses against vivax malaria," says del Portillo.



More information: Míriam Díaz-Varela et al, Proteomics study of human cord blood reticulocyte-derived exosomes, *Scientific Reports* (2018). DOI: 10.1038/s41598-018-32386-2

Provided by Barcelona Institute for Global Health

Citation: A new approach to developing a vaccine against vivax malaria (2018, September 21) retrieved 2 May 2024 from <u>https://medicalxpress.com/news/2018-09-approach-vaccine-vivax-malaria.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.